male, the mean age was 43 years, with a range of 20 to 88. The clinical presentation of 75% of the patients was jaundice. Abdominal pain or pruritus were the second and third most frequent symptoms. Pruritus, as an isolated symptom, occurred in 13%. Thirteen percent of the patients were asymptomatic. The liver function test showed a cholestatic pattern in 94% of the patients. The diagnosis was confirmed by cholangio-resonance in 78%, endoscopic retrograde cholangiopancreatography in 6% and a combination of both in 16%. Fifty percent of the patients had associated Inflammatory Bowel Disease (93.75% were UC). One of the 32 patients (3%) presented PSC associated to Autoimmune Hepatitis. The complications were: progression to liver cirrhosis in 53%, bacterial cholangitis in 13%, bile duct stones in 6%. Sixteen percent underwent Liver Transplantation and 28% did not present any complications.

Conclusions: The first series of patients with PSC in our country is reported. The characteristics of this pathology, in this series, do not differ significantly from the characteristics published in most other countries.

https://doi.org/10.1016/j.aohep.2024.101725

P-112 ADVANCED FIBROSIS IN PATIENTS WITH LIVER STEATOSIS MEASURED BY FIBROSCAN AND ITS ASSOCIATED FACTORS

Máximo Cattaneo[1], Daniela Simian[1], Katherine Rojas[2], Jaime Poniachik[1]

[1] *HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE, Santiago, Chile*
[2] *HOSPITAL CLÍNICO UNIVERSIDAD DE CHIE, Santiago, Chile*

Conflict of interest: No

Introduction and Objectives: The prevalence of fatty liver disease associated with metabolic dysfunction (MASLD) has been increasing. Its most advanced stage is F3-F4 fibrosis with eventual decompensation and the need for liver transplantation. The aim was to identify the factors associated with advanced fibrosis as observed by liver elastography (Fibroscan®) in patients with MASLD and in a subgroup of patients with diabetes mellitus (DM).

Patients / Materials and Methods: Retrospective, descriptive study of patients with MASLD who underwent Fibroscan® in our center between October 2023 and June 2024. Patients were categorized into 2 groups: without advanced fibrosis (F0-F2) and with advanced fibrosis (F3-F4). Sociodemographic variables, clinical and laboratory history were analyzed between groups, using chi2 and Mann-Whitney in Stata 16.0 software.

Results and Discussion: Of 1297 Fibroscan® performed in the study period, 577 (44%) patients met MASLD criteria for analysis; 62% women, median age 58 years (interquartile range 48 – 66); Advanced fibrosis was presented in 132 (33%) patients. The table compares the sociodemographic and clinical characteristics of the patients according to the degree of fibrosis. Older age, Fonasa health insurance, hypertension, diabetes mellitus, obesity, higher level of glycosylated hemoglobin and higher CAP (Coefficient Attenuated Parameter) were associated with advanced fibrosis. A sub-analysis was carried out in patients with MASLD and DM (n = 151), observing that Fonasa health insurance (65% vs 47%; p=0.032) and obesity (67% vs 43%; p=0.004) were associated with advanced fibrosis.

Conclusions: In patients with MASLD who present cardio metabolic risk factors such as older age, hypertension, diabetes mellitus, and obesity, the presence of advanced fibrosis should be evaluated to prevent associated complications.

Table. Sociodemographic characterization and clinical history of patients with hepatic steatosis according to the degree of fibrosis

	Advanced fibrosis (F3 – F4) N = 132	Without advanced fibrosis (F0 – F2) N = 445	P value
Age in years (median;IQR)	60 (52 – 68)	57 (47 – 65)	**0.0031**
Gender (n, %)			
Female	79 (60)	277 (61)	0.756
Male	53 (40)	172 (39)	
Health insurance			
Public (Fonasa)	79 (60)	175 (41)	**< 0.0001**
Private	53 (40)	254 (59)	
Comorbidities (n, %)			
Hypertension	70 (53)	164 (37)	**0.001**
Diabetes Mellitus	60 (45)	91 (26)	**< 0.0001**
Insulin resistance	23 (17)	83 (19)	0.749
Dyslipidemia	9 (7)	40 (9)	0.432
Obesity	87 (66)	218 (49)	**0.001**
Body Mass Index (median;IQR)	32 (29 – 35.7)	29,9 (27.3 – 32.5)	**< 0.0001**
Laboratory tests (median;IQR)			
Glucose (n = 204)	100 (90 – 119)	99 (158 – 211)	0.183
Insulin (n = 59)	22.9 (15.2 – 36.2)	13.1 (10.1 – 20.9)	**0.020**
Glycosylated hemoglobin (n = 125)	6 (5.8 – 7.1)	5.7 (5.4 – 6.1)	**0.0031**
Cholesterol (n = 231)	164 (141 – 198)	185 (158 – 211)	**0.0044**
LDL (n = 167)	90 (67 – 114)	103 (75 – 128)	0.058
HDL (n = 167)	50 (41 – 57)	50 (39 – 62)	0.985
Triglycerides (n = 199)	123 (100 – 172)	139 (100 – 205)	0.467
CAP (median;IQR)	309 (266 – 345)	297.5 (268 – 322)	**0.026**
Steatosis			
Mild	32 (24)	106 (24)	0.095
Moderate	17 (13)	94 (21)	
Severe	83 (63)	245 (55)	

IQR: Interquartile range; CAP: Coefficient Attenuated Parameter

https://doi.org/10.1016/j.aohep.2024.101726

P-113 EVALUATION OF THE MELNA AGIB SCALE TO PREDICT MORTALITY IN PATIENTS WITH CIRRHOSIS AND VARICEAL HEMORRHAGE

Miguel Yael Carmona Castillo[1], Claudia Leticia Dorantes Nava[1], María De Fatima Higuera De La Tijera[1], Jose Luis Pérez Hernández[1]

[1] *HOSPITAL GENERAL DE MÉXICO, CIUDAD DE MÉXICO, México*

Conflict of interest: No

Introduction and Objectives: Patients with decompensated cirrhosis are at risk of variceal hemorrhage, which increases the risk of mortality. Validated scales exist to assess this risk, but there is currently no scale that evaluates the risk of variceal hemorrhage and death simultaneously. The MELDNa AGIB (acute gastrointestinal bleeding) scale incorporates sodium (Na) levels, albumin levels, the corrected QT interval (QTc), and a history of hemorrhage to calculate mortality at 6 weeks. While it has been evaluated in other centers, further studies are needed to validate its utility. To evaluate the MELDNa-AGIB scale for predicting the risk of mortality in decompensated cirrhotic patients.

Patients / Materials and Methods: This was a retrospective, analytical, observational study conducted on a cohort of patients with decompensated cirrhosis and variceal hemorrhage. The MELDNAA-GIB scale was calculated for each patient and compared with other scoring systems, including MELD, MELD NA, MELD LACTATE, and MELD 3.0, to assess its effectiveness. Statistical analysis involved the construction of ROC curves to determine the prognostic value of each